Investors who own more than 5% of a class must file a Schedule 13D or 13G. Each filer's latest filing for 87184Q107 since 12/18/2024, largest first.
| Filer | % of Class | Filed | ||
|---|---|---|---|---|
| Under 5%, checked the "5 percent or less" box, or amended by a later filing (2) | ||||
|
Invus Global Management, LLC
13G/A
|
3.8% |
2/12/2025
Event 12/31/2024
|
||
| Invus Public Equities, L.P. | 3.8% | |||
| Invus Public Equities Advisors, LLC | 3.8% | |||
| Invus Global Management, LLC | 3.8% | |||
| Siren, L.L.C. | 3.8% | |||
| Avicenna Life Sci Master Fund LP | 0% | |||
| Avicenna Life Sci Master GP LLC | 0% | |||
| Ulys, L.L.C. | 0% | |||
| Raymond Debbane | 3.8% | |||
|
Deep Track Capital, LP
13G/A
|
0% |
2/14/2025
Event 12/31/2024
|
||
| Deep Track Capital, LP | 0% | |||
| Deep Track Biotechnology Master Fund, Ltd. | 0% | |||
| David Kroin | 0% | |||
| Period | Filings | Shares, Excl. Options | Value, Excl. Options |
|---|---|---|---|
| 2023 Q1 | 1 | 219 | $585.00 |
| 2022 Q4 | 1 | 219 | $786.00 |
| 2022 Q3 | 3 | 882 k | $5.68 M |
| 2022 Q2 | 71 | 35.6 M | $34.2 M |
| 2022 Q1 | 98 | 44.6 M | $53.1 M |
| 2021 Q4 | 97 | 51.4 M | $167 M |
| 2021 Q3 | 106 | 50.1 M | $223 M |
| 2021 Q2 | 109 | 50.9 M | $276 M |
| 2021 Q1 | 113 | 63.8 M | $476 M |
| 2020 Q4 | 110 | 57.2 M | $619 M |
| 2020 Q3 | 95 | 46.0 M | $406 M |
| 2020 Q2 | 81 | 44.7 M | $464 M |
| 2020 Q1 | 68 | 49.8 M | $295 M |
| 2019 Q4 | 74 | 42.6 M | $294 M |
| 2019 Q3 | 65 | 43.1 M | $446 M |
| 2019 Q2 | 71 | 34.9 M | $322 M |
| 2019 Q1 | 66 | 23.8 M | $218 M |
| 2018 Q4 | 71 | 22.5 M | $125 M |
| 2018 Q3 | 82 | 20.8 M | $247 M |
| 2018 Q2 | 81 | 20.6 M | $211 M |
| 2018 Q1 | 62 | 18.5 M | $240 M |
| 2017 Q4 | 73 | 15.9 M | $154 M |
| 2017 Q3 | 68 | 15.2 M | $224 M |
| 2017 Q2 | 49 | 15.6 M | $251 M |
| 2017 Q1 | 47 | 12.9 M | $206 M |
| 2016 Q4 | 43 | 13.0 M | $158 M |
| 2016 Q3 | 35 | 12.8 M | $176 M |
| 2016 Q2 | 12 | 12.5 M | $207 M |